Human Aβ1–42 was purchased from AnaSpec (Fremont, CA, USA) and dissolved in sterile NaOH 10 mM at a concentration of 221.5 μM following the manufacturer’s instructions. In order to obtain the fibrillary form, Aβ1–42 solution was diluted in PBS 1X and let aggregate for 24 h at 37 °C [47 (link),48 (link),49 (link)].
The selective PPAR-α antagonist GW6471 was purchased by Tocris Bioscience (Bristol, UK) and dissolved in DMSO, whereas a preparation containing co-ultra PEALut (PEA and Luteolin co-ultramicronized, 10:1 by mass; a kind gift of Epitech Group SpA, Saccolongo, Italy) was dissolved in Pluronic F-68 (Sigma-Aldrich, St. Louis, MO, USA) and sonicated for 20 min in a water bath until complete dissolution.
Primary astrocytes were treated with Aβ1–42 1 μM in the presence or absence of the following substances: co-ultra PEALut (3 µm) and GW6471 (3 μM). Concentrations and schedule of treatments were chosen based on the available literature [23 (link),32 (link),40 (link),50 (link),51 (link)] and according to the results of neutral red uptake assays. All reagents were lipopolysaccharide-free.
After 48 h of treatment, astrocytes and oligodendrocytes were collected separately and processed for analyses.
Free full text: Click here